Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC
The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.
Source: empr.com
Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.
AstraZeneca's Enhertu approved in the US for HER2-low metastatic breast cancer
AstraZeneca's Lynparza approved in EU for early breast cancer
AstraZeneca's Enhertu approved in the EU for HER2-positive mBC
Cancer treatments may benefit from lessons of pandemic set-backs